Tourmaline Bio, Inc.
TRML
$13.40
-$0.84-5.90%
| Weiss Ratings | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -23.91% | |||
| 30-Day Total Return | 6.35% | |||
| 60-Day Total Return | -37.47% | |||
| 90-Day Total Return | -42.98% | |||
| Year to Date Total Return | -35.08% | |||
| 1-Year Total Return | -38.53% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -52.20% | |||
| 52-Week Low % Change | 19.97% | |||
| Price | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $29.79 | |||
| 52-Week Low Price | $11.87 | |||
| 52-Week Low Price (Date) | Feb 24, 2025 | |||
| 52-Week High Price (Date) | Oct 18, 2024 | |||
| Valuation | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 365.76M | |||
| Enterprise Value | 107.70M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.88 | |||
| Earnings Per Share Growth | -90.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.22 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $13.40 | |||
| Enterprise Value/EBITDA (TTM) | -1.20 | |||
| Enterprise Value/EBIT | -1.20 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 25.80M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 481 9832 | |||
| Address | 27 West 24th Street New York, NY 10010 | |||
| Website | www.tourmalinebio.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -21.60% | |||
| Return on Equity | -- | |||
| Income Statement | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -89.69M | |||
| EBIT (TTM) | -89.73M | |||
| Net Income (TTM) | -73.21M | |||
| Net Income Avl. to Common (TTM) | -73.21M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -72.34% | |||
| EPS Diluted (TTM) | -2.88 | |||
| EPS Diluted Growth (Q YOY) | -6.92% | |||
| Balance Sheet | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 258.30M | |||
| Cash Per Share (Q) | $10.01 | |||
| Total Current Assets (Q) | 268.84M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 300.05M | |||
| Current Ratio (Q) | 30.176 | |||
| Book Value Per Share (Q) | $11.71 | |||
| Total Assets (Q) | 309.00M | |||
| Total Current Liabilities (Q) | 8.91M | |||
| Total Debt (Q) | 244.00K | |||
| Total Liabilities (Q) | 8.95M | |||
| Total Common Equity (Q) | 300.05M | |||
| Cash Flow | TRML - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -194.31M | |||
| Cash from Financing (TTM) | 161.35M | |||
| Net Change in Cash (TTM) | -110.22M | |||
| Levered Free Cash Flow (TTM) | -50.17M | |||
| Cash from Operations (TTM) | -77.26M | |||
